Search results
Results from the WOW.Com Content Network
The 30S subunit is the target of antibiotics such as tetracycline and gentamicin. [11] These antibiotics specifically target the prokaryotic ribosomes, hence their usefulness in treating bacterial infections in eukaryotes. Tetracycline interacts with H27 in the small subunit as well as binding to the A-site in the large subunit. [11]
As human and bacteria both have ribosomes, streptomycin has significant side effects in humans. At low concentrations, however, streptomycin inhibits only bacterial growth. [18] Streptomycin is an antibiotic that inhibits both Gram-positive and Gram-negative bacteria, [19] and is therefore a useful broad-spectrum antibiotic.
These viral DNA sequences enable the nuclease to target foreign (viral) rather than self (bacterial) DNA. [ 205 ] Although the function of CRISPR-Cas9 in nature is to protect bacteria, the DNA sequences in the CRISPR component of the system can be modified so that the Cas9 nuclease targets bacterial resistance genes or bacterial virulence genes ...
A well-known member of this antibiotic class, chloramphenicol, acts by inhibiting peptide bond formation, with recent 3D-structural studies showing two different binding sites depending on the species of ribosome. Numerous mutations in domains of the 23S rRNA with Peptidyl transferase activity have resulted in antibiotic resistance.
The following antibiotics bind to the 30S subunit of the ribosome: Aminoglycosides [17] Tetracyclines [17] The following antibiotics bind to the 50S ribosomal subunit: Chloramphenicol [17] Clindamycin [17] Linezolid [17] (an oxazolidinone) Macrolides [17] Telithromycin [17] Streptogramins [17] Retapamulin [18]
Eukaryotic ribosomes are known to bind to transcripts in a mechanism unlike the one involving the 5' cap, at a sequence called the internal ribosome entry site. This process is not dependent on the full set of translation initiation factors (although this depends on the specific IRES) and is commonly found in the translation of viral mRNA. [9]
Scientists say they have developed a new type of antibiotic to treat a bacteria that is resistant to most current antibiotics and kills a large percentage of people with an invasive infection.
The structure of the kasugamycin-70S ribosome complex from Escherichia coli has been determined by X-ray crystallography at 3.5-A resolution. The drug binds within the messenger RNA channel of the 30S subunit between the universally conserved G926 and A794 nucleotides in 16S ribosomal RNA, which are sites of kasugamycin resistance.